Search Result
Results for "
lipid lowering
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-106535
-
|
Febuprol
|
Others
|
Metabolic Disease
|
|
Valbilan (Febuprol) is a choleretic agent. Valbilan exhibits spasmolytic and lipid lowering effects .
|
-
-
- HY-101701
-
-
-
- HY-N0458
-
-
-
- HY-W800776
-
|
1,2-Dioleoyl-3-dimethyl-hydroxyethylammonium bromide
|
Liposome
|
Others
|
|
DORI is a cationic lipid that can deliver plasmid DNA in vitro. DORI has lower cytotoxicity and high transfection efficiency .
|
-
-
- HY-115914
-
|
|
LDLR
|
Others
|
|
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
|
-
-
- HY-162703
-
|
|
AMPK
|
Metabolic Disease
|
|
Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
|
-
-
- HY-135594
-
|
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
|
4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
|
-
-
- HY-15387
-
-
-
- HY-16421
-
|
(-)-DRF 2725; NNC 61-0029
|
PPAR
|
Metabolic Disease
|
|
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
|
-
-
- HY-165512
-
|
|
LDLR
|
Cardiovascular Disease
|
|
Nicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL).
|
-
-
- HY-109567
-
|
PD-72953
|
LDLR
|
Metabolic Disease
Inflammation/Immunology
|
|
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
|
-
-
- HY-130587
-
|
Piperazine sultosylate; A-585
|
Others
|
Metabolic Disease
|
|
Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .
|
-
-
- HY-109567A
-
|
PD-72953 calcium
|
LDLR
|
Metabolic Disease
Inflammation/Immunology
|
|
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
|
-
-
- HY-173014
-
-
-
- HY-115938
-
-
-
- HY-U00340
-
|
|
PPAR
|
Metabolic Disease
|
|
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
|
-
-
- HY-N6653
-
-
-
- HY-W144096
-
|
|
Drug Metabolite
|
Metabolic Disease
Cancer
|
|
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .
|
-
-
- HY-119546
-
|
PNLA
|
Free Fatty Acid Receptor
|
Inflammation/Immunology
|
|
Pinolenic acid (PNLA) is a polyunsaturated fatty acid that can be isolated from Pinus orientalis and Pinus pinaster seed oil. Pinolenic acid has anti-inflammatory and lipid-lowering activities .
|
-
-
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
-
- HY-117196
-
-
-
- HY-124281
-
|
|
NF-κB
Akt
Autophagy
PI3K
|
Others
|
|
9(R)-PAHSA is a R-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
|
-
-
- HY-14925
-
-
-
- HY-124281A
-
|
|
Drug Isomer
NF-κB
|
Others
|
|
9(S)-PAHSA is a S-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
|
-
-
- HY-101637
-
|
JT 501
|
PPAR
|
Metabolic Disease
|
|
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
|
-
-
- HY-101692
-
-
-
- HY-N0458R
-
|
|
Fatty Acid Synthase (FASN)
|
Metabolic Disease
|
|
Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .
|
-
-
- HY-123632
-
|
|
Cytochrome P450
|
Others
|
|
(3S,5S)-Atorvastatin sodium salt is a pregnane X receptor (PXR) activator and the inactive enantiomer of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor with lipid-lowering capabilities .
|
-
-
- HY-B1189
-
|
Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid
|
HMG-CoA Reductase (HMGCR)
Autophagy
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .
|
-
-
- HY-W134326
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
Cancer
|
|
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
|
-
-
- HY-P99696
-
|
LIB003
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
|
-
-
- HY-129459
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
α-Tocotrienol is an isoform of vitamin E and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.
|
-
-
- HY-100976
-
-
-
- HY-122778
-
|
|
p38 MAPK
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
δ-Tocotrienol is a Vitamin E in vegetables, fruits, seeds, nuts, grains and oils. Vitamin E has become well known for its role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.
|
-
-
- HY-161938
-
|
|
PCSK9
LDLR
|
Metabolic Disease
|
|
BRD8518 is a PCSK9 inhibitor (EC50=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases .
|
-
-
- HY-19418
-
|
|
PPAR
|
Others
|
|
KRP-101 is a compound that regulates the expression of genes related to lipid metabolism. It is a PPARα agonist that can highly sensitively regulate the expression of genes such as apolipoprotein A-IV, which may be related to lowering serum triglycerides and increasing HDL.
|
-
-
- HY-170692
-
|
|
Akt
PI3K
NF-κB
|
Metabolic Disease
|
|
Hypoglycemic agent 3 (Compound H26), a derivative of corosolic acid, exhibits lipid-lowering and significant hypoglycemic effects and can be used as a hypoglycemic agent. Hypoglycemic agent 3 inhibits insulin resistance by targeting MCCC1 and can be used in the study of type 2 diabetes .
|
-
-
- HY-148626
-
|
|
PCSK9
|
Metabolic Disease
|
|
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
|
-
-
- HY-16620
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DF 461 is a sterol synthase inhibitor with significant inhibitory activity. DF 461 shows high selectivity for the liver and can effectively inhibit cholesterol synthesis in rat liver. DF 461 has shown the effect of lowering plasma lipids in repeated dosing studies in non-rodents .
|
-
-
- HY-B0258
-
-
-
- HY-W006405
-
|
|
Estrogen Receptor/ERR
|
Cardiovascular Disease
Cancer
|
|
Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .
|
-
-
- HY-N0712
-
|
|
Autophagy
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .
|
-
-
- HY-113820
-
|
|
PPAR
|
Metabolic Disease
|
|
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .
|
-
-
- HY-W001171
-
-
-
- HY-131306B
-
|
Gaidic acid
|
Biochemical Assay Reagents
|
Others
|
|
2-Hexadecenoic acid is a natural unsaturated fatty acid. It is ubiquitously present in various animal and plant tissues, especially adipose tissue and certain vegetable oils, such as macadamia nut oil. 2-Hexadecenoic acid has unique chemical properties that make it an important component of cell membranes and storage lipids, and participates in various metabolic processes such as lipid metabolism and inflammation. It's also been linked to potential health benefits, including improved insulin sensitivity and a lower risk of heart disease.
|
-
-
- HY-134769
-
-
-
- HY-16643
-
Linerixibat
Maximum Cited Publications
11 Publications Verification
GSK2330672
|
Apical Sodium-Dependent Bile Acid Transporter
|
Metabolic Disease
Inflammation/Immunology
|
|
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .
|
-
-
- HY-N13205
-
|
|
Others
|
Metabolic Disease
|
|
Mulberry Extract is a mulberry extract, and its components include: Anthocyanidins. Mulberry Extract regulates sugar and lipid metabolism, lowers blood sugar and increases insulin secretion. Its blood sugar regulating effect may be attributed to the phytochemicals it contains, mainly 1-deoxynojirimycin, flavonoids, phenolic compounds and polysaccharides. .
|
-
-
- HY-N0224
-
|
|
Influenza Virus
|
Infection
Metabolic Disease
Cancer
|
|
Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .
|
-
-
- HY-B0258S
-
|
CI-719-d6
|
PPAR
Cytochrome P450
|
Cardiovascular Disease
Metabolic Disease
|
|
Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
|
-
- HY-129459R
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
α-Tocotrienol (Standard) is the analytical standard of α-Tocotrienol. This product is intended for research and analytical applications. α-Tocotrienol is an isoform of vitamin E and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.
|
-
- HY-109523
-
|
|
HMG-CoA Reductase (HMGCR)
Ferroptosis
|
Cardiovascular Disease
Cancer
|
|
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
- HY-B1028
-
-
- HY-B2078
-
|
|
Neurokinin Receptor
|
Inflammation/Immunology
|
|
Eprazinone can enhance lung function and arterial oxygen levels and can be used in the study of chronic bronchitis. Higher doses of eprazinone increased phospholipid levels and decreased neutral lipid content in bronchoalveolar lavage (BAL) fluid, but had no effect on protein and cell levels in BAL. Eprazinone dose-dependently reduced short-circuit current (Isc), primarily by reducing chloride secretion at lower concentrations and affecting sodium and chloride transport at higher doses. Eprazinone may exert its anti-inflammatory effects by regulating BAL lipid composition and airway ion transport .
|
-
- HY-130345
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
|
-
- HY-122778R
-
|
|
p38 MAPK
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
δ-Tocotrienol (Standard) is the analytical standard of δ-Tocotrienol. This product is intended for research and analytical applications. δ-Tocotrienol is a Vitamin E in vegetables, fruits, seeds, nuts, grains and oils. Vitamin E has become well known for its role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.
|
-
- HY-129458
-
|
|
HMG-CoA Reductase (HMGCR)
Ferroptosis
|
Cardiovascular Disease
Cancer
|
|
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
- HY-116175
-
|
|
LDLR
|
Metabolic Disease
|
|
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .
|
-
- HY-159595
-
|
|
LDLR
PCSK9
|
Metabolic Disease
Inflammation/Immunology
|
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
|
-
- HY-100313A
-
|
|
Farnesyl Transferase
HCV
|
Infection
Metabolic Disease
|
|
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
|
-
- HY-W006405R
-
|
|
Others
|
Cardiovascular Disease
Cancer
|
|
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .
|
-
- HY-B2171AR
-
|
|
Apoptosis
|
Infection
Cancer
|
|
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .
|
-
- HY-N0712R
-
|
|
Autophagy
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Typhaneoside (Standard) is the analytical standard of Typhaneoside. This product is intended for research and analytical applications. Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .
|
-
- HY-B0258R
-
|
CI-719 (Standard)
|
PPAR
Cytochrome P450
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
|
-
- HY-P10337
-
|
|
GCGR
GLP Receptor
|
Metabolic Disease
Endocrinology
|
|
OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
|
-
- HY-17408
-
-
- HY-120657
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
|
|
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
|
-
- HY-N13221
-
|
|
Bacterial
Reactive Oxygen Species
Fungal
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Apple Cider Vinegar Powder is a soluble powdered form of apple cider vinegar. Apple Cider Vinegar Powder has anti-bacterial, anti-oxidant, and antibiotic properties and can help maintain the acid-base balance in the blood. Apple Cider Vinegar Powder can lower blood sugar and lipid levels. Apple Cider Vinegar Powder is used in research related to tumors, diabetes, and cardiovascular diseases .
|
-
- HY-B1028R
-
|
|
Endogenous Metabolite
SARS-CoV
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Pantethine (Standard) is the analytical standard of Pantethine. This product is intended for research and analytical applications. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
|
-
- HY-109523S
-
|
|
Ferroptosis
HMG-CoA Reductase (HMGCR)
Isotope-Labeled Compounds
|
Cardiovascular Disease
Cancer
|
|
Cerivastatin-d3 sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
- HY-100313
-
|
|
Farnesyl Transferase
HCV
|
Metabolic Disease
|
|
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
|
-
- HY-B1028S
-
|
D-Pantethine-15N2; LBF disulfide-15N2
|
Isotope-Labeled Compounds
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Pantethine- 15N2 is the 15N2 labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
|
-
- HY-117167
-
|
|
Thyroid Hormone Receptor
|
Cancer
|
|
KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
|
-
- HY-135595
-
|
|
Estrogen Receptor/ERR
Drug Metabolite
|
Metabolic Disease
|
|
6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A .
|
-
- HY-117459
-
|
|
PPAR
|
Metabolic Disease
|
|
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
|
-
- HY-164853
-
|
|
Pyroptosis
NOD-like Receptor (NLR)
ERK
FGFR
AMPK
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .
|
-
- HY-B0258S1
-
-
- HY-17408R
-
|
Compactin(Standard); ML236B (Standard)
|
HMG-CoA Reductase (HMGCR)
Bacterial
Autophagy
Apoptosis
Antibiotic
|
Infection
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Mevastatin (Standard) is the analytical standard of Mevastatin. This product is intended for research and analytical applications. Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .
|
-
- HY-N14035
-
|
|
ATP Citrate Lyase
|
Cardiovascular Disease
Metabolic Disease
|
|
Garcinia cambogia extract contains several active compounds, including hydroxycitric acid (HCA) (an ECC inhibitor), xanthones, benzophenones, hydroxycitric acid (an ATP-citrate lyase inhibitor). Garcinia cambogia extract lowers the body weight gain, visceral fat accumulation, blood and hepatic lipid concentrations, and plasma insulin and leptin levels in a high-fat diet (HFD)-induced obesity mouse model. Garcinia cambogia extract is promising for research of fatty liver, dyslipidemia, hyperinsulinemia and hyperleptinemia rendered by HFD .
|
-
- HY-106281A
-
|
PPD 10558 hemicalcium
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
Metabolic Disease
|
|
Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of ≥320 mg/kg/d (rat developmental toxicity), ≥12.5 mg/kg/d (rabbit maternal toxicity), ≥25 mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.
|
-
- HY-N13083
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
PCSK9-IN-28 (Compound C11) is a PCSK9 inhibitor that can be isolated from Euphorbia esula. By binding to HNF1α, PCSK9-IN-28 inhibits PCSK9 transcription by binding to HNF1α and affecting its nuclear distribution, thereby enhancing LDLR and promoting LDL uptake. PCSK9-IN-28 exhibits significant lipid-lowering activity in the high-fat diet (HFD) mouse model and can be used in the study of hyperlipidemia .
|
-
- HY-N0807
-
|
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .
|
-
- HY-W015924
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
|
-
- HY-18540
-
|
|
DAGL
MAGL
|
Metabolic Disease
Inflammation/Immunology
|
|
KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC50 of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC50=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages .
|
-
- HY-145858
-
|
|
Ferroptosis
|
Cancer
|
|
Chalcones A-N-5 is a trihydroxy chalcone derivative compound. Chalcones A-N-5 doesn’t show cytotoxicity at the concentration lower than 100 µM (with IC50 > 1 mM), but has a significant effect on promoting cell proliferation. Chalcones A-N-5 potentially promotes neuronal cell growth in the damaged brain tissue. Chalcones A-N-5 also inhibits ferroptosis induced by RSL or erastin and reduces the lipid peroxidation levels induced by Aβ1-42 protein aggregation. Chalcones A-N-5 is a promising molecular skeleton candidate for further development of lead compound for in vivo test to research AD .
|
-
- HY-W015924R
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
|
-
- HY-124187
-
|
Ethyl pinolenate
|
Biochemical Assay Reagents
|
Others
|
|
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
|
-
- HY-N7075
-
Inulin
2 Publications Verification
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W134326
-
|
|
Biochemical Assay Reagents
|
|
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
|
-
- HY-124187
-
|
Ethyl pinolenate
|
Drug Delivery
|
|
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
|
-
- HY-131306B
-
|
Gaidic acid
|
Drug Delivery
|
|
2-Hexadecenoic acid is a natural unsaturated fatty acid. It is ubiquitously present in various animal and plant tissues, especially adipose tissue and certain vegetable oils, such as macadamia nut oil. 2-Hexadecenoic acid has unique chemical properties that make it an important component of cell membranes and storage lipids, and participates in various metabolic processes such as lipid metabolism and inflammation. It's also been linked to potential health benefits, including improved insulin sensitivity and a lower risk of heart disease.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10337
-
|
|
GCGR
GLP Receptor
|
Metabolic Disease
Endocrinology
|
|
OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
- HY-P99696
-
|
LIB003
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0458
-
-
-
- HY-N6653
-
-
-
- HY-W144096
-
-
-
- HY-119546
-
-
-
- HY-14925
-
-
-
- HY-B1189
-
-
-
- HY-129459
-
-
-
- HY-W006405
-
-
-
- HY-N0712
-
-
-
- HY-N0458R
-
-
-
- HY-W001171
-
-
-
- HY-N0224
-
-
-
- HY-129459R
-
-
-
- HY-B1028
-
-
-
- HY-W006405R
-
|
|
Structural Classification
Flavonoids
Leguminosae
Glycine max (L.) merr
Source classification
Plants
Isoflavones
|
Others
|
|
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .
|
-
-
- HY-B2171AR
-
|
|
Quinones
Structural Classification
Microorganisms
Anthraquinones
Source classification
Phenols
Polyphenols
|
Apoptosis
|
|
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .
|
-
-
- HY-N0712R
-
|
|
Flavonols
Structural Classification
Flavonoids
Typhaceae
Typha angustifolia L.
Source classification
Phenols
Polyphenols
Plants
|
Autophagy
|
|
Typhaneoside (Standard) is the analytical standard of Typhaneoside. This product is intended for research and analytical applications. Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .
|
-
-
- HY-17408
-
-
-
- HY-120657
-
-
-
- HY-B1028R
-
|
|
Structural Classification
Natural Products
Source classification
Endogenous metabolite
|
Endogenous Metabolite
SARS-CoV
|
|
Pantethine (Standard) is the analytical standard of Pantethine. This product is intended for research and analytical applications. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
|
-
-
- HY-100313
-
|
|
Structural Classification
Alkaloids
Carbazole Alkaloids
|
Farnesyl Transferase
HCV
|
|
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
|
-
-
- HY-N14035
-
|
|
Structural Classification
Natural Products
Guttiferae
Source classification
Garcinia cambogia Desr.
Plants
|
ATP Citrate Lyase
|
|
Garcinia cambogia extract contains several active compounds, including hydroxycitric acid (HCA) (an ECC inhibitor), xanthones, benzophenones, hydroxycitric acid (an ATP-citrate lyase inhibitor). Garcinia cambogia extract lowers the body weight gain, visceral fat accumulation, blood and hepatic lipid concentrations, and plasma insulin and leptin levels in a high-fat diet (HFD)-induced obesity mouse model. Garcinia cambogia extract is promising for research of fatty liver, dyslipidemia, hyperinsulinemia and hyperleptinemia rendered by HFD .
|
-
-
- HY-N13083
-
-
-
- HY-N0807
-
-
-
- HY-W015924
-
-
-
- HY-W015924R
-
|
|
Structural Classification
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
|
Endogenous Metabolite
|
|
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
|
-
-
- HY-N7075
-
Inulin
2 Publications Verification
|
Structural Classification
Classification of Application Fields
Source classification
Metabolic Disease
Plants
Compositae
Endogenous metabolite
Sophora tomentosa L.
Human Gut Microbiota Metabolites
Polysaccharides
Microorganisms
Disease Research Fields
Saccharides
|
Endogenous Metabolite
|
|
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0258S
-
|
|
|
Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
|
-
-
- HY-109523S
-
|
|
|
Cerivastatin-d3 sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
|
-
-
- HY-B1028S
-
|
|
|
Pantethine- 15N2 is the 15N2 labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
|
-
-
- HY-B0258S1
-
|
|
|
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W800776
-
|
1,2-Dioleoyl-3-dimethyl-hydroxyethylammonium bromide
|
|
Cationic Lipids
|
|
DORI is a cationic lipid that can deliver plasmid DNA in vitro. DORI has lower cytotoxicity and high transfection efficiency .
|
-
- HY-W134326
-
|
|
|
Fillers
|
|
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
|
-
- HY-130345
-
|
|
|
Phospholipids
|
|
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
